As part of our company mission we feel that it is always important to stay up on anti-aging breakthrough discovery. Artificial Intelligence and anti-aging is one major focus for us.
Which is why Curly D by Curly Davenport entered the beauty marketplace to be like no other beauty company that came before us…Making sure that we educate the beauty consumer with resourceful knowledge is something we take very seriously.
Recently, we discovered scientists at the Biogerontology Research Foundation, Insilico Medicine and Life Extension use Deep Learning-based Artificial Intelligence to Score natural compounds according to safety and gene- and pathway-level similarity to metformin and rapamycin.
The paper can be accessed at http://www.aging-us.com/article/101319
Metformin, a common type 2 diabetes drug, and rapamycin, a common anti-rejection drug, have both been shown to have substantial anti-aging and anti-cancer effects in a variety of model organisms. However, both compounds have known side effects and are regulated drugs for existing disease indications, factors that problematize their off-label use as healthspan extending drugs.
In this study, the researchers applied deep-learned neural networks to profile the safety and gene- and pathway-level similarity of more than 800 natural compounds to metformin and rapamycin, in an effort to identify natural compounds that can mimic the effects of these anti-cancer and anti-aging drugs while remaining free of the adverse effects associated with them.
Their analysis identified many novel candidate metformin and rapamycin mimetics that have been previously unreported as such. In particular, they identified allantoin and ginsenoside as strong mimetics of metformin, epigallocatechin gallate and isoliquiritigenin as strong mimetics of rapamycin, and withaferin A as a strong mimetic of both. Additionally, their analysis also identified four previously unexplored natural compounds as fairly strong mimetic of rapamycin.
These findings are significant because, as naturally occurring compounds, such nutraceuticals are not subject to regulation by the FDA and other regulatory bodies. Furthermore, because the researchers induced a deep-learning based classification of the safety profiles associated with these compounds, the novel candidate mimetics the study identified are likely to have less adverse effects than metformin and rapamycin, though this needs to be further validated by clinical testing.